Try our mobile app

Switch to company model in classical logic    *

General information

Country: JAPAN

Sector: Drug Manufacturers — Specialty and Generic

Takeda Pharmaceutical Company Limited is engaged in research and development, manufacturing, sales and marketing, and import and export of pharmaceutical drugs. The Company focuses on the core therapeutic areas of oncology, gastrointestinal, and central nervous system disease.



Growth: Bad revenue growth rate -11.6%, there is slowdown compared to average historical growth rates 4.2%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +27.7%. On average the margin is improving unsteadily. Gross margin is high, +69.5%.

Cash Flow Generation: Dividend yield for the last twelve months 4.1%. Free cash flow yield 17.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 17.4% higher than minimum and 14.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.6x by EV / Sales multiple

Key Financials (Download financials)

Ticker: TAK
Share price, USD:  (+1.0%)14.575
year average price 14.28  


year start price 14.06 2024-08-13

min close price 12.89 2025-01-22

max close price 15.46 2025-06-30

current price 14.58 2025-08-12
Common stocks: 3 130 324 000

Dividend Yield:  4.1%
FCF Yield LTM: 17.3%
EV / LTM EBITDA: 9.6x
EV / EBITDA annualized: 9.3x
Last revenue growth (y/y):  -11.6%
Last growth of EBITDA (y/y):  -10.5%
Historical revenue growth:  +4.2%
Historical growth of EBITDA:  +22.8%
EV / Sales: 2.7x
Margin (EBITDA LTM / Revenue): 27.7%
Fundamental value created in LTM:
Market Cap ($m): 45 624
Net Debt ($m): 26 644
EV (Enterprise Value): 72 268
Price to Book: 1.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-30seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript

2025-07-17seekingalpha.com

Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector

2025-07-14businesswire.com

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

2025-06-25businesswire.com

Takeda Announces New Assignments of Directors

2025-05-11seekingalpha.com

Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise

2025-05-08youtube.com

Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO

2025-05-08businesswire.com

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

2025-05-02zacks.com

TAK or DSNKY: Which Is the Better Value Stock Right Now?

2025-04-16zacks.com

TAK vs. DSNKY: Which Stock Is the Better Value Option?

2025-04-08accessnewswire.com

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TAK TAK TAK TAK TAK TAK TAK TAK TAK
reportedCurrency JPY JPY JPY JPY JPY JPY JPY JPY JPY
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-05-29 2024-05-29 2024-02-02 2023-09-30 2023-06-23 2023-06-28 2022-12-31 2022-09-30
acceptedDate 2024-10-31 06:28:39 2024-05-29 06:24:59 2024-05-29 06:24:59 2024-02-02 06:16:40 2023-09-30 00:00:00 2023-06-23 06:13:42 2023-06-28 06:07:10 2022-12-30 19:00:00 2022-09-29 20:00:00
calendarYear 2025 2025 2024 2024 2024 2024 2023 2023 2023
period Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 1 176 038M 1 207 990M 1 050 869M 1 111 186M 1 043 089M 1 058 618M 956 156M 1 096 551M 1 002 307M
costOfRevenue 394 311M 549 785M 382 501M 379 481M 343 582M 321 114M 309 772M 335 973M 305 445M
grossProfit 781 727M 658 205M 668 368M 731 705M 699 507M 737 504M 646 384M 760 578M 696 862M
grossProfitRatio 0.665 0.545 0.636 0.658 0.671 0.697 0.676 0.694 0.695
researchAndDevelopmentExpenses 175 564M 168 463M 195 856M 187 381M 183 946M 162 741M 160 944M 174 629M 154 145M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 268 282M 270 030M 285 234M 267 520M 252 952M 248 113M 254 796M 262 299M 248 734M
otherExpenses 153 634M 216 214M 0 -1 210M 0 0 142 080M 176 660M 189 546M
operatingExpenses 597 480M 654 707M 481 090M 665 290M 748 850M 568 933M 557 820M 613 588M 592 425M
costAndExpenses 991 791M 1 041 661M 863 591M 1 044 771M 1 092 432M 890 047M 867 592M 949 561M 897 870M
interestIncome 4 116M 30 677M 5 992M 21 789M -2 143M 26 455M 7 783M 41 679M 14 782M
interestExpense 68 454M 59 691M 47 187M 66 568M 46 520M 59 575M 42 933M 79 749M 53 803M
depreciationAndAmortization 192 452M 192 220M 186 744M 187 061M 182 696M 171 501M 163 696M 216 792M 181 741M
ebitda 380 278M 384 548M 374 022M 314 889M 190 782M 366 109M 252 258M 363 782M 286 179M
ebitdaratio 0.323 0.318 0.356 0.283 0.183 0.346 0.264 0.332 0.286
operatingIncome 184 247M 166 329M 187 278M 104 914M -49 341M 168 571M 88 562M 146 990M 104 438M
operatingIncomeRatio 0.157 0.138 0.178 0.094 -0.047 0.159 0.093 0.134 0.104
totalOtherIncomeExpensesNet -64 875M -29 725M -238 542M 39 624M 2 025M -418M -40 647M -39 837M -39 889M
incomeBeforeTax 119 372M 136 604M -51 264M 61 260M -95 980M 135 033M 47 915M 107 153M 64 549M
incomeBeforeTaxRatio 0.102 0.113 -0.049 0.055 -0.092 0.128 0.05 0.098 0.064
incomeTaxExpense 27 266M 41 304M -44 528M -44 496M -48 009M 45 627M 16 779M -11 996M 2 817M
netIncome 92 046M 95 248M -3 018M 105 720M -48 030M 89 395M 31 134M 119 127M 61 742M
netIncomeRatio 0.078 0.079 -0.003 0.095 -0.046 0.084 0.033 0.109 0.062
eps 0 59.94 -1.92 67.38 -30.68 57.52 9.99 38.32 19.89
epsdiluted 0 59.94 -1.92 66.7 -30.68 57.12 9.65 37.93 19.74
weightedAverageShsOut 0 1 589M 1 569M 1 569M 1 565M 1 554M 3 104M 3 109M 3 105M
weightedAverageShsOutDil 0 1 589M 1 569M 1 585M 1 565M 1 565M 3 140M 3 141M 3 127M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TAK TAK TAK TAK TAK TAK TAK TAK TAK
reportedCurrency JPY JPY JPY JPY JPY JPY JPY JPY JPY
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-05-29 2024-05-29 2024-02-02 2023-09-30 2023-06-23 2023-06-28 2022-12-31 2022-09-30
acceptedDate 2024-10-31 06:28:39 2024-05-29 06:24:59 2024-05-29 06:24:59 2024-02-02 06:16:40 2023-09-30 00:00:00 2023-06-23 06:13:42 2023-06-28 06:07:10 2022-12-30 19:00:00 2022-09-29 20:00:00
calendarYear 2025 2025 2024 2024 2024 2024 2023 2023 2023
period Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 859 015M 804 272M 205 190M 288 359M 318 051M 316 380M 533 530M 685 141M 798 137M
shortTermInvestments 47 200M 359 493M 252 610M 29 045M 15 756M 52 229M 20 174M 41 467M 31 932M
cashAndShortTermInvestments 906 215M 804 272M 457 800M 317 404M 333 807M 368 609M 553 704M 726 608M 830 069M
netReceivables 721 056M 755 425M 697 610M 743 079M 788 066M 825 481M 681 693M 779 872M 800 536M
inventory 1 206 431M 1 276 739M 1 209 869M 1 169 640M 1 155 866M 1 083 374M 986 457M 927 286M 953 450M
otherCurrentAssets 220 311M 271 096M 193 301M 179 394M 178 219M 179 883M 160 867M 154 824M 155 636M
totalCurrentAssets 3 054 013M 3 107 532M 2 558 580M 2 428 830M 2 462 066M 2 472 017M 2 397 956M 2 595 946M 2 745 616M
propertyPlantEquipmentNet 1 887 620M 2 085 382M 1 989 777M 1 841 499M 1 894 136M 1 795 315M 1 691 229M 1 656 416M 1 760 327M
goodwill 5 160 112M 5 733 710M 5 410 067M 5 111 287M 5 301 017M 5 182 128M 4 790 723M 4 690 949M 4 994 632M
intangibleAssets 3 770 620M 4 366 147M 4 274 683M 4 097 022M 4 402 421M 4 514 084M 4 269 657M 3 765 757M 4 187 055M
goodwillAndIntangibleAssets 8 930 732M 10 099 857M 9 684 750M 9 208 309M 9 703 438M 9 696 212M 9 060 380M 8 456 706M 9 181 687M
longTermInvestments 277 314M 87 688M 430 608M 372 918M 416 364M 393 529M 378 857M 369 469M 425 766M
taxAssets 338 304M 0 393 865M 316 689M 336 211M 375 522M 366 003M 359 393M 394 752M
otherNonCurrentAssets 85 016M 847 224M 51 212M 54 703M 59 672M 60 143M 63 325M 66 774M 80 699M
totalNonCurrentAssets 11 518 986M 13 120 151M 12 550 212M 11 794 118M 12 409 821M 12 320 721M 11 559 794M 10 908 758M 11 843 231M
otherAssets 1 000 000 0 0 -1 000 000 2M 0 0 1 000 000 0
totalAssets 14 573 000M 16 227 683M 15 108 792M 14 222 947M 14 871 889M 14 792 738M 13 957 750M 13 504 705M 14 588 847M
accountPayables 413 335M 468 882M 319 955M 483 666M 421 078M 440 924M 649 233M 381 109M 388 616M
shortTermDebt 624 101M 438 743M 433 459M 370 292M 274 841M 416 860M 339 600M 372 019M 568 228M
taxPayables 141 439M 162 201M 109 906M 112 446M 130 218M 242 756M 232 377M 188 779M 189 568M
deferredRevenue 0 0 109 906M 594 913M 787 875M 770 529M 0 0 0
otherCurrentLiabilities 1 208 362M 1 395 376M 1 449 783M 833 297M 883 823M 873 428M 1 493 107M 1 483 681M 1 434 876M
totalCurrentLiabilities 2 387 237M 2 465 202M 2 313 103M 2 282 168M 2 367 617M 2 501 741M 2 481 940M 2 236 809M 2 391 720M
longTermDebt 4 427 092M 5 658 630M 4 476 501M 4 293 872M 4 404 363M 4 330 254M 4 042 741M 3 914 884M 4 168 417M
deferredRevenueNonCurrent 0 0 553 431M 156 665M 153 936M 201 419M 0 0 0
deferredTaxLiabilitiesNonCurrent 46 619M 0 113 777M 133 036M 228 719M 269 549M 270 620M 388 681M 465 746M
otherNonCurrentLiabilities 790 455M 304 618M 377 976M 614 599M 646 229M 568 106M 807 778M 787 833M 4 526 794M
totalNonCurrentLiabilities 5 264 166M 5 963 248M 5 521 685M 5 198 172M 5 433 247M 5 369 328M 5 121 139M 5 091 398M 5 483 638M
otherLiabilities 0 1 000 000 0 0 0 0 0 0 0
capitalLeaseObligations 0 616 388M 553 431M 542 126M 574 874M 0 0 0 0
totalLiabilities 7 651 403M 8 428 451M 7 834 788M 7 480 340M 7 800 864M 7 871 069M 7 603 079M 7 328 207M 7 875 358M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 1 694 660M 1 676 596M 1 676 596M 1 676 543M 1 676 503M 1 676 411M 1 676 345M 1 676 334M 1 676 330M
retainedEarnings 1 431 684M 1 338 192M 1 391 203M 1 396 838M 1 446 018M 1 490 097M 1 541 146M 1 507 720M 1 530 200M
accumulatedOtherComprehensiveIncomeLoss 0 3 074 713M 2 509 310M 1 989 669M 2 287 968M 0 0 0 0
othertotalStockholdersEquity 3 794 410M 1 708 916M 1 696 155M 1 678 884M 1 659 863M 3 754 544M 3 136 631M 2 991 924M 3 506 399M
totalStockholdersEquity 6 920 754M 7 798 417M 7 273 264M 6 741 934M 7 070 352M 6 921 052M 6 354 122M 6 175 978M 6 712 929M
totalEquity 6 921 597M 7 799 232M 7 274 005M 6 742 607M 7 071 025M 6 921 669M 6 354 122M 6 175 978M 6 712 929M
totalLiabilitiesAndStockholdersEquity 14 573 000M 16 227 683M 15 108 793M 14 222 947M 14 871 889M 14 792 738M 13 957 750M 13 504 705M 14 588 847M
minorityInterest 843M 815M 741M 673M 673M 617M 549M 520M 0
totalLiabilitiesAndTotalEquity 14 573 000M 16 227 683M 15 108 793M 14 222 947M 14 871 889M 14 792 738M 13 957 750M 13 504 705M 14 588 847M
totalInvestments 324 514M 447 181M 683 218M 401 963M 432 120M 445 758M 399 031M 410 936M 457 698M
totalDebt 5 051 193M 5 480 985M 5 463 391M 4 664 164M 4 679 204M 4 747 114M 4 382 341M 4 286 903M 4 736 645M
netDebt 4 192 178M 4 676 713M 5 258 201M 4 375 805M 4 361 153M 4 430 734M 3 848 811M 3 601 762M 3 938 508M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TAK TAK TAK TAK TAK TAK TAK TAK TAK
reportedCurrency JPY JPY JPY JPY JPY JPY JPY JPY JPY
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-31 2024-05-29 2024-05-29 2024-02-02 2023-09-30 2023-06-23 2023-06-28 2022-12-31 2022-09-30
acceptedDate 2024-10-31 06:28:39 2024-05-29 06:24:59 2024-05-29 06:24:59 2024-02-02 06:16:40 2023-09-30 00:00:00 2023-06-23 06:13:42 2023-06-28 06:07:10 2022-12-30 19:00:00 2022-09-29 20:00:00
calendarYear 2025 2025 2024 2024 2024 2024 2023 2023 2023
period Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome 92 107M 95 299M -3 018M 105 755M -47 970M 89 406M 31 135M 119 150M 61 732M
depreciationAndAmortization 192 452M 192 220M 186 744M 187 061M 182 696M 171 501M 161 410M 176 880M 167 827M
deferredIncomeTax 27 266M 41 304M -44 528M -44 496M -48 009M 45 627M 16 779M -11 996M 2 817M
stockBasedCompensation 21 554M 15 386M 18 188M 18 706M 18 535M 15 442M 14 849M 16 488M 17 043M
changeInWorkingCapital -70 810M -189 979M 99 062M -166 022M 1 590M -150 947M 143 392M 51 304M -31 491M
accountsReceivables -10 035M -47 744M 73 897M 14 288M 17 292M 0 0 0 0
inventory -41 139M -10 079M 12 747M -50 552M -49 349M -28 589M -44 915M -18 462M -6 660M
accountsPayables 0 -37 455M -30 482M 70 266M -15 023M 0 0 0 0
otherWorkingCapital -19 636M -94 701M 42 900M -200 024M 48 670M -122 358M 188 307M 69 766M -24 831M
otherNonCashItems 18 394M 16 074M 307 012M 45 447M 92 063M -78 629M -73 872M 26 403M 3 065M
netCashProvidedByOperatingActivities 280 963M 170 304M 272 474M 146 451M 198 905M 92 400M 293 693M 378 229M 220 993M
investmentsInPropertyPlantAndEquipment -49 473M -57 441M -64 326M -77 124M -70 043M -269 237M -444 080M -50 624M -40 609M
acquisitionsNet 5 389M 0 -13 704M -26 250M -7M 372M 7 958M 0 0
purchasesOfInvestments -10 052M -31 672M -2 042M -2 460M -1 590M -674M -4 710M -747M -1 761M
salesMaturitiesOfInvestments 17 798M 5 317M 6 932M 458M 88M 543M 1 701M 2 153M 12 222M
otherInvestingActivites -38 793M -72 897M -3 921M 30 107M 10 973M 2 466M 639M 2 528M 2 942M
netCashUsedForInvestingActivites -75 131M -156 693M -77 060M -75 269M -60 579M -266 530M -438 492M -46 690M -27 206M
debtRepayment -69 547M 429 613M -56 979M -96 507M -157 070M -110 634M -85 976M -266 199M -10 767M
commonStockIssued 0 0 0 0 0 190 185M 0 0 0
commonStockRepurchased 0 -1 882M 0 0 0 -2 326M 0 0 0
dividendsPaid -9 199M -138 110M -9 126M -138 251M -9 065M -130 746M -10 419M -128 990M -11 134M
otherFinancingActivites -31 299M 26 760M -73 194M 136 998M 25 480M -4 257M 89 795M -39 766M -29 975M
netCashUsedProvidedByFinancingActivities -110 045M 316 381M -36 533M -97 760M -140 655M -57 778M -6 600M -434 955M -51 876M
effectOfForexChangesOnCash -41 784M 17 220M 10 560M -3 115M 4 000M 14 759M -212M -9 579M 10 235M
netChangeInCash 54 003M 599 082M -83 169M -29 692M 1 671M -217 150M -151 611M -112 996M 152 146M
cashAtEndOfPeriod 859 015M 804 272M 205 190M 288 359M 318 051M 316 380M 533 530M 685 141M 798 137M
cashAtBeginningOfPeriod 805 012M 205 190M 288 359M 318 051M 316 380M 533 530M 685 141M 798 137M 645 991M
operatingCashFlow 280 963M 159 375M 272 474M 146 451M 198 905M 92 400M 293 693M 378 229M 220 993M
capitalExpenditure -92 452M -137 798M -64 326M -77 124M -70 043M -269 237M -444 080M -50 624M -40 609M
freeCashFlow 188 511M 21 577M 208 148M 69 327M 128 862M -176 837M -150 387M 327 605M 180 384M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-31 ET (fiscal 2025 q2)
2024 q2
2024-08-02 ET (fiscal 2025 q1)
2024 q1
2024-05-09 ET (fiscal 2023 q4)
2023 q3
2023-10-27 ET (fiscal 2023 q2)
2023 q2
2023-07-27 ET (fiscal 2023 q1)
2022 q4
2023-02-02 ET (fiscal 2023 q3)
2022 q1
2022-05-12 ET (fiscal 2022 q4)
2021 q4
2022-02-03 ET (fiscal 2022 q3)
2021 q3
2021-10-29 ET (fiscal 2022 q2)
2021 q2
2021-07-31 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-31 06:05 ET
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
2024-10-24 12:00 ET
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
2024-10-09 02:00 ET
Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking
2024-09-24 07:00 ET
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
2024-09-19 12:00 ET
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
2024-09-18 14:00 ET
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
2024-08-07 10:45 ET
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2024-07-31 06:06 ET
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
2024-06-26 07:05 ET
Takeda Announces New Assignments of Directors
2024-06-24 07:00 ET
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
2024-06-23 02:30 ET
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
2024-06-21 20:00 ET
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
2024-06-18 12:00 ET
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
2024-06-17 10:45 ET
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
2024-06-14 12:00 ET
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
2024-06-11 12:00 ET
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
2024-06-03 10:45 ET
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
2024-05-31 13:57 ET
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2024-05-14 12:00 ET
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
2024-05-09 06:07 ET
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
2024-04-26 12:30 ET
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
2024-04-22 08:10 ET
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
2024-04-18 23:00 ET
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
2024-04-08 12:00 ET
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
2024-03-27 12:53 ET
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
2024-03-27 12:53 ET
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
2024-03-26 23:07 ET
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
2024-03-26 12:00 ET
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2024-03-19 16:20 ET
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
2024-03-13 12:00 ET
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
2024-02-27 04:30 ET
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
2024-02-12 13:00 ET
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
2024-02-08 23:00 ET
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
2024-02-01 06:54 ET
Takeda Announces Chief Financial Officer Succession
2024-02-01 06:02 ET
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
2024-01-29 16:10 ET
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2024-01-29 07:00 ET
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2024-01-18 12:00 ET
Takeda Named Global Top Employer for Seventh Consecutive Year
2024-01-16 13:00 ET
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2023-12-21 21:00 ET
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
2023-12-15 13:16 ET
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2023-12-05 13:00 ET
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
2023-11-27 13:00 ET
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
2023-11-09 20:50 ET
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2023-11-08 22:54 ET
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
2023-11-07 15:00 ET
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
2023-10-26 06:00 ET
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
2023-10-18 20:30 ET
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
2023-10-17 23:30 ET
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
2023-10-17 23:30 ET
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
2023-10-03 20:50 ET
Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
2023-10-02 20:30 ET
Takeda Provides Update on EXKIVITY® (mobocertinib)
2023-09-27 20:25 ET
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
2023-09-25 12:44 ET
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
2023-09-20 12:00 ET
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
2023-09-13 14:00 ET
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
2023-09-13 12:00 ET
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
2023-09-11 10:45 ET
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
2023-07-27 06:00 ET
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
2023-07-26 21:11 ET
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
2023-06-25 14:45 ET
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2023-06-20 12:45 ET
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
2023-06-16 00:30 ET
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
2023-06-16 00:00 ET
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
2023-06-15 14:30 ET
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
2023-05-26 12:00 ET
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
2023-05-25 20:30 ET
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
2023-05-17 01:00 ET
U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2023-05-11 06:40 ET
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
2023-04-27 12:00 ET
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
2023-04-26 13:03 ET
Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
2023-04-11 12:00 ET
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
2023-04-03 12:30 ET
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
2023-03-30 11:00 ET
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
2023-03-30 07:00 ET
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
2023-03-27 14:33 ET
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
2023-03-18 11:00 ET
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
2023-03-14 13:30 ET
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
2023-02-18 22:30 ET
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
2023-02-08 23:30 ET
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
2023-02-03 23:48 ET
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
2023-02-02 06:00 ET
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
2023-01-23 08:00 ET
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
2023-01-23 08:00 ET
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
2023-01-17 04:00 ET
Takeda Named Global Top Employer for Sixth Consecutive Year
2023-01-11 13:36 ET
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
2023-01-05 11:45 ET
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
2022-12-22 01:00 ET
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
2022-12-19 19:30 ET
Takeda’s Phase 3 AURORA Study Provides Evidence of Maribavir’s Clinically Meaningful and Durable Effect in Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint
2022-12-13 12:00 ET
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
2022-12-09 13:00 ET
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
2022-12-08 11:45 ET
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
2022-12-06 05:00 ET
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
2022-11-22 20:57 ET
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
2022-11-17 13:00 ET
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
2022-11-11 07:00 ET
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
2022-10-27 06:00 ET
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
2022-10-20 11:00 ET
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
2022-10-14 11:30 ET
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
2022-10-05 12:09 ET
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
2022-09-29 12:00 ET
Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies
2022-09-19 12:00 ET
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
2022-09-16 12:00 ET
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
2022-09-13 14:00 ET
Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
2022-08-22 13:57 ET
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
2022-07-28 06:00 ET
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance

SEC forms

Show financial reports only

SEC form 6
2025-07-31 10:03 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-31 10:03 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-30 10:02 ET
Takeda Pharmaceutical reported for 2025 q2
SEC form 6
2025-07-30 10:02 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-14 10:05 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-09 10:01 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-09 10:01 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-08 10:03 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-01 10:03 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-06-30 10:06 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-30 10:06 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-25 10:03 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-25 10:02 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-12 10:04 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-10 10:08 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-06 10:08 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-02 10:06 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-02 10:01 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:27 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:27 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:20 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:20 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:14 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:14 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:12 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:12 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-14 10:03 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-08 10:19 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-08 10:19 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-08 10:14 ET
Takeda Pharmaceutical reported for 2025 q1
SEC form 6
2025-05-08 10:14 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-04-22 10:08 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-04-14 10:12 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-04-01 10:07 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-03-26 10:01 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-03-13 10:00 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-03-03 11:46 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-03-03 11:03 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-02-13 11:06 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-01-30 06:29 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-01-30 06:28 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-01-30 06:25 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-01-30 06:24 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-01-30 06:23 ET
Takeda Pharmaceutical reported for 2024 q4
SEC form 6
2025-01-30 06:23 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2024-12-02 06:00 ET
Takeda Pharmaceutical published news for 2024 q3
SEC form 6
2024-12-02 06:00 ET
Takeda Pharmaceutical published news for 2024 q3
SEC form 6
2024-10-31 06:28 ET
Takeda Pharmaceutical reported for 2024 q3
SEC form 6
2024-10-31 06:21 ET
Takeda Pharmaceutical reported for 2024 q3
SEC form 6
2024-10-31 06:21 ET
Takeda Pharmaceutical published news for 2024 q3
SEC form 6
2024-10-31 06:19 ET
Takeda Pharmaceutical published news for 2024 q3
SEC form 6
2024-09-26 06:01 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-31 06:02 ET
Takeda Pharmaceutical reported for 2024 q2
SEC form 6
2024-07-31 06:02 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-10 06:04 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-10 06:04 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-09 06:05 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-02 06:20 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-01 06:33 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-01 06:33 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-06-26 06:02 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-26 06:01 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-17 06:46 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-11 06:23 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-10 06:10 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-07 06:07 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-07 06:04 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-03 06:45 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-03 06:26 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:24 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:24 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-21 06:02 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-04-19 06:12 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-04-19 06:12 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-04-15 06:02 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-03-27 06:34 ET
Takeda Pharmaceutical published news for 2023 q4
SEC form 6
2024-01-16 06:01 ET
Takeda Pharmaceutical published news for 2023 q4
SEC form 6
2023-12-14 06:01 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-12-14 06:01 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-11-30 06:01 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-11-30 06:01 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-10-26 06:22 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-10-26 06:20 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-10-18 06:21 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-10-18 06:20 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-10-02 06:17 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-09-28 06:17 ET
Takeda Pharmaceutical published news for 2023 q2
SEC form 6
2023-09-11 06:50 ET
Takeda Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-27 06:05 ET
Takeda Pharmaceutical reported for 2023 q2
SEC form 6
2023-07-12 06:07 ET
Takeda Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-06 06:18 ET
Takeda Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-03 06:02 ET
Takeda Pharmaceutical published news for 2023 q2
SEC form 6
2023-06-28 06:07 ET
Takeda Pharmaceutical reported for 2023 q1
SEC form 6
2023-06-28 06:02 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-28 06:00 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-23 06:13 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-23 06:10 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-09 06:03 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-01 06:02 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-30 06:20 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-30 06:19 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-30 06:14 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-30 06:11 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-11 06:10 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-11 06:07 ET
Takeda Pharmaceutical reported for 2023 q1
SEC form 6
2023-03-30 06:19 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-03-20 06:17 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-03-16 06:03 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-03-01 06:03 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-02-10 06:00 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-02-09 06:00 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-02-07 06:05 ET
Takeda Pharmaceutical reported for 2022 q4
SEC form 6
2023-02-02 06:04 ET
Takeda Pharmaceutical reported for 2022 q4
SEC form 6
2023-01-10 06:01 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-01-05 06:46 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2022-12-21 06:01 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-12-13 07:00 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-12-08 06:46 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-11-30 06:28 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-11-04 06:01 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-10-27 06:01 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-10-14 07:36 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-10-04 06:06 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-08-23 06:13 ET
Takeda Pharmaceutical published news for 2022 q2
SEC form 6
2022-08-04 06:07 ET
Takeda Pharmaceutical published news for 2022 q2
SEC form 6
2022-07-28 06:09 ET
Takeda Pharmaceutical published news for 2022 q2
SEC form 6
2022-07-11 06:05 ET
Takeda Pharmaceutical published news for 2022 q2
SEC form 6
2022-07-05 06:09 ET
Takeda Pharmaceutical published news for 2022 q2
SEC form 6
2022-06-29 06:05 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-29 06:02 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-29 06:01 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-29 06:01 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-24 06:08 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-10 06:00 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-01 06:08 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-31 06:20 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-31 06:18 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-31 06:14 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-31 06:11 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-31 06:07 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-12 06:05 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-11 06:11 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-11 06:06 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-19 06:07 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-14 06:07 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-13 06:41 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-01 06:14 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-01 06:07 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-03-22 06:13 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-03-14 06:08 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-03-01 06:19 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-14 06:02 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-10 06:03 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-03 06:18 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-03 06:11 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-03 06:09 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-13 06:01 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-11 06:04 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-11 06:02 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-05 06:02 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2021-12-27 06:03 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-12-16 06:02 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-12-14 06:01 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-12-01 06:00 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-30 06:04 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-12 06:01 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-05 06:02 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-01 06:37 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-01 06:04 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-28 06:26 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-28 06:12 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-08 06:03 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-06 06:03 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-01 06:03 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-09-07 06:05 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-09-07 06:02 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-09-01 08:01 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-30 06:02 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-26 06:06 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-18 06:02 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-06 06:10 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-06 06:06 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-06 06:03 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-02 06:15 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-07-30 06:02 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-07-20 06:05 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-07-19 06:02 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-07-08 06:21 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-07-02 06:07 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-06-29 07:38 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-29 06:06 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-29 06:03 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-29 06:02 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-29 06:01 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-21 06:05 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-21 06:01 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-28 06:07 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-28 06:04 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-28 06:03 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-28 06:01 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-26 20:55 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-21 06:04 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-11 06:28 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-11 06:24 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-11 06:20 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-11 06:15 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-11 06:08 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-10 06:06 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-04-06 06:29 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-04-02 08:02 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-04-01 06:15 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-03-31 06:11 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-03-31 06:09 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-03-11 06:07 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-03-05 06:00 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-26 06:01 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-24 06:07 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-12 06:04 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-04 06:07 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-04 06:05 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-01-21 06:08 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2020-12-17 06:01 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-12-08 06:01 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-11-30 06:18 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-11-24 06:06 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-11-10 06:01 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-29 06:04 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-29 06:02 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-29 06:01 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-09 06:11 ET
Takeda Pharmaceutical published news for 2020 q3